Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.

@article{Gotfried2012EfficacyOI,
  title={Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.},
  author={Mark H. Gotfried and Edward M. Kerwin and David S Lawrence and Cheryl Lassen and Benjamin Kramer},
  journal={COPD},
  year={2012},
  volume={9 6},
  pages={
          629-36
        }
}
Indacaterol is an inhaled, once-daily, long-acting ®(2)-agonist for the treatment of COPD. Most previous studies were conducted with doses of 150 and/or 300 μg once-daily, and data with the 75 μg dose are limited. Two identically designed studies were, therefore, conducted to evaluate the efficacy and safety of the 75 μg once-daily dose. In two double-blind studies conducted in the USA, patients with moderate-to-severe COPD were randomized to treatment with indacaterol 75 μg once-daily (n = 163… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Similar Papers

Loading similar papers…